Biotech Innovations SEQENS recently launched PeptiCode HP-9, signaling strong momentum in biotech peptides and specialty biotech solutions. This presents a cross-sell opportunity to introduce related pharmaceutical intermediates, GMP-grade materials, and custom synthesis capabilities to accelerate peptide-based product development.

Strategic Realignment Sale of Botanical Actives and In Vitro Diagnostics activities to Solabia indicates a strategic portfolio adjustment. This could create open discussions for SEQENS to outsource or co-develop high-value natural ingredients or IVD-related materials, while offering compatible API and intermediate production capabilities.

Personal Care Growth Active focus on personal care with biobased emollients like AdvensProtect 2-EHG Green and Caprylyl Glycol signals demand for sustainable ingredients. Propose expanded supply of biobased actives, specialty excipients, and formulation support to CPG customers seeking green, compliant solutions.

Global Manufacturing Footprint With 15 manufacturing sites and 5 R&D centers across Europe, North America, and Asia, SEQENS offers a scalable global supply chain. Position as a partner for multinational pharma and cosmetics clients needing regional manufacturing, tech-transfer, and rapid scale-up for new molecules.

Leadership and Collaboration New CEO appointment and ongoing investments in advanced technologies suggest a growth-oriented roadmap. Offer strategic collaborations around custom synthesis, process optimization, and digitalized operations (e.g., SAP, data analytics) to win long-term API, intermediate, and specialty ingredient contracts.